Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
|Articles|December 17, 2013
The Results of the IBIS II Trial
Author(s)Charles L. Shapiro, MD
Charles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.
Advertisement
Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.
Clinical Pearls:
- IBIS II is a prevention study in over 3,000 women who were randomized to anastrozole vs placebo
- Anastrozole proved to be 50% effective in presenting breast cancer, primarily ER+ breast cancer, compared to the placebo
- There was only a 10% difference in the grades of musculoskeletal arthralgias when comparing anastrozole to the placebo
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5